- Home
- ROIV vs ESS Comparison
ROIV vs ESS Comparison
Compare ROIV & ESS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | ESS |
|---|---|---|
| Founded | 2014 | 1971 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 16.9B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | ROIV | ESS |
|---|---|---|
| Price | $21.70 | $258.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 18 |
| Target Price | $21.94 | ★ $292.97 |
| AVG Volume (30 Days) | ★ 6.7M | 413.4K |
| Earning Date | 11-10-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 3.99% |
| EPS Growth | N/A | ★ 53.64 |
| EPS | N/A | ★ 13.15 |
| Revenue | $20,329,000.00 | ★ $1,916,711,000.00 |
| Revenue This Year | N/A | $3.80 |
| Revenue Next Year | $376.94 | $3.59 |
| P/E Ratio | ★ N/A | $19.59 |
| Revenue Growth | N/A | ★ 9.37 |
| 52 Week Low | $8.73 | $243.25 |
| 52 Week High | $22.45 | $316.29 |
Technical Indicators
Market Signals| Indicator | ROIV | ESS |
|---|---|---|
| Relative Strength Index (RSI) | 62.44 | 52.99 |
| Support Level | $20.14 | $250.78 |
| Resistance Level | $21.48 | $261.25 |
| Average True Range (ATR) | 0.71 | 3.88 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 65.96 | 60.13 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 258 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.